keyword
MENU ▼
Read by QxMD icon Read
search

Primaquine

keyword
https://www.readbyqxmd.com/read/29456374/factors-affecting-primaquine-combination-treatment-in-malaria-patients-in-selangor-malaysia
#1
Norliza Mat Ariffin, Farida Islahudin, Mohd Makmor-Bakry, Endang Kumolosasi, Mohd Hafizi A Hamid
Introduction: Primaquine is vital for the management of liver-stage Plasmodium vivax and Plasmodium ovale malaria. However, primaquine effectiveness is dependent on various factors and differs between populations. Therefore, this study was conducted to identify factors that affect the length of stay and relapse during primaquine combination treatment in malaria-infected patients in the local setting. Materials and Methods: A retrospective study on the use of primaquine combination among P...
October 2017: Journal of Pharmacy & Bioallied Sciences
https://www.readbyqxmd.com/read/29444080/promising-approach-to-reducing-malaria-transmission-by-ivermectin-sporontocidal-effect-against-plasmodium-vivax-in-the-south-american-vectors-anopheles-aquasalis-and-anopheles-darlingi
#2
Yudi T Pinilla, Stefanie C P Lopes, Vanderson S Sampaio, Francys S Andrade, Gisely C Melo, Alessandra S Orfanó, Nágila F C Secundino, Maria G V B Guerra, Marcus V G Lacerda, Kevin C Kobylinski, Karin S Escobedo-Vargas, Victor M López-Sifuentes, Craig A Stoops, G Christian Baldeviano, Joel Tarning, Gissella M Vasquez, Paulo F P Pimenta, Wuelton M Monteiro
BACKGROUND: The mosquito resistance to the insecticides threatens malaria control efforts, potentially becoming a major public health issue. Alternative methods like ivermectin (IVM) administration to humans has been suggested as a possible vector control to reduce Plasmodium transmission. Anopheles aquasalis and Anopheles darlingi are competent vectors for Plasmodium vivax, and they have been responsible for various malaria outbreaks in the coast of Brazil and the Amazon Region of South America...
February 14, 2018: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29433507/sudden-spleen-rupture-in-a-plasmodium-vivax-infected-patient-undergoing-malaria-treatment
#3
Aleix Elizalde-Torrent, Fernando Val, Ingrid Cardoso C Azevedo, Wuelton M Monteiro, Luiz C L Ferreira, Carmen Fernández-Becerra, Hernando A Del Portillo, Marcus V G Lacerda
BACKGROUND: Splenomegaly is one of the most common features of malaria. However, spontaneous splenic rupture, although unusual, represents a severe complication often leading to death. It is mostly seen in acute infection and primary attack, and it is most commonly associated with Plasmodium vivax. Here, a case of spontaneous splenic rupture diagnosed with a portable ultrasound apparatus shortly after starting treatment and with recurrent parasitaemia after splenectomy, is reported. CASE DESCRIPTION: In November 2015, a 45-year-old Brazilian man presented to the hospital in Manaus with fever, headache and myalgia...
February 13, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29426330/molecular-evidence-for-relapse-of-an-imported-plasmodium-ovale-wallikeri-infection
#4
Luzia Veletzky, Mirjam Groger, Heimo Lagler, Julia Walochnik, Herbert Auer, Hans-Peter Fuehrer, Michael Ramharter
BACKGROUND: Malaria caused by Plasmodium ovale spp. has been neglected by and large from research and has received only little scientific attention during the past decades. Ovale malaria is considered to feature relapses by liver hypnozoites although scientific evidence for this paradigm is scarce. CASE PRESENTATION: Here, the case of a 16-year-old male, who presented with fevers to the outpatient department in Vienna, Austria, after travelling to Uganda and Papua New Guinea is described...
February 9, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29422384/efficacy-and-safety-of-primaquine-and-methylene-blue-for-prevention-of-plasmodium-falciparum-transmission-in-mali-a-phase-2-single-blind-randomised-controlled-trial
#5
Alassane Dicko, Michelle E Roh, Halimatou Diawara, Almahamoudou Mahamar, Harouna M Soumare, Kjerstin Lanke, John Bradley, Koualy Sanogo, Daouda T Kone, Kalifa Diarra, Sekouba Keita, Djibrilla Issiaka, Sekou F Traore, Charles McCulloch, Will J R Stone, Jimee Hwang, Olaf Müller, Joelle M Brown, Vinay Srinivasan, Chris Drakeley, Roly Gosling, Ingrid Chen, Teun Bousema
BACKGROUND: Primaquine and methylene blue are gametocytocidal compounds that could prevent Plasmodium falciparum transmission to mosquitoes. We aimed to assess the efficacy and safety of primaquine and methylene blue in preventing human to mosquito transmission of P falciparum among glucose-6-phosphate dehydrogenase (G6PD)-normal, gametocytaemic male participants. METHODS: This was a phase 2, single-blind, randomised controlled trial done at the Clinical Research Centre of the Malaria Research and Training Centre (MRTC) of the University of Bamako (Bamako, Mali)...
February 5, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29407988/machine-learning-prioritizes-synthesis-of-primaquine-ureidoamides-with-high-antimalarial-activity-and-attenuated-cytotoxicity
#6
Jurica Levatić, Kristina Pavić, Ivana Perković, Lidija Uzelac, Katja Ester, Marijeta Kralj, Marcel Kaiser, Matthias Rottmann, Fran Supek, Branka Zorc
Primaquine (PQ) is a commonly used drug that can prevent the transmission of Plasmodium falciparum malaria, however toxicity limits its use. We prepared five groups of PQ derivatives: amides 1a-k, ureas 2a-k, semicarbazides 3a,b, acylsemicarbazides 4a-k and bis-ureas 5a-v, and evaluated them for antimalarial activity in vitro against the erythrocytic stage of P. falciparum NF54. Particular substituents, such as trityl (in 2j and 5r) and methoxybenzhydryl (in 3b and 5v) were associated with a favorable cytotoxicity-to-activity ratio...
January 31, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29393511/primaquine-or-other-8-aminoquinolines-for-reducing-plasmodium-falciparum-transmission
#7
REVIEW
Patricia M Graves, Leslie Choi, Hellen Gelband, Paul Garner
BACKGROUND: The 8-aminoquinoline (8AQ) drugs act on Plasmodium falciparum gametocytes, which transmit malaria from infected people to mosquitoes. In 2012, the World Health Organization (WHO) recommended a single dose of 0.25 mg/kg primaquine (PQ) be added to malaria treatment schedules in low-transmission areas or those with artemisinin resistance. This replaced the previous recommendation of 0.75 mg/kg, aiming to reduce haemolysis risk in people with glucose-6-phosphate dehydrogenase deficiency, common in people living in malarious areas...
February 2, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29390987/cyp2d6-activity-and-the-risk-of-recurrence-of-plasmodium-vivax-malaria-in-the-brazilian-amazon-a-prospective-cohort-study
#8
Larissa W Brasil, Fernanda Rodrigues-Soares, Ana B Santoro, Anne C G Almeida, Andrea Kühn, Rajendranath Ramasawmy, Marcus V G Lacerda, Wuelton M Monteiro, Guilherme Suarez-Kurtz
BACKGROUND: CYP2D6 pathway mediates the activation of primaquine into active metabolite(s) in hepatocytes. CYP2D6 is highly polymorphic, encoding CYP2D6 isoforms with normal, reduced, null or increased activity. It is hypothesized that Plasmodium vivax malaria patients with defective CYP2D6 function would be at increased risk for primaquine failure to prevent recurrence. The aim of this study was to investigate the association of CYP2D6 polymorphisms and inferred CYP2D6 phenotypes with malaria recurrence in patients from the Western Brazilian Amazon, following chloroquine/primaquine combined therapy...
February 1, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29389671/a-controlled-human-malaria-infection-model-enabling-evaluation-of-transmission-blocking-interventions
#9
Katharine A Collins, Claire Yt Wang, Matthew Adams, Hayley Mitchell, Melanie Rampton, Suzanne Elliott, Isaie J Reuling, Teun Bousema, Robert Sauerwein, Stephan Chalon, Jörg J Möhrle, James S McCarthy
BACKGROUND: Drugs and vaccines that can interrupt the transmission of Plasmodium falciparum will be important for malaria control and elimination. However, models for early clinical evaluation of candidate transmission-blocking interventions are currently unavailable. Here we describe a new model for evaluating malaria transmission from humans to Anopheles mosquitoes using controlled human malaria infection (CHMI). METHODS: Seventeen healthy malaria-naïve volunteers underwent CHMI by intravenous inoculation of P...
February 1, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29370800/a-novel-immortalized-hepatocyte-like-cell-line-imhc-supports-in-vitro-liver-stage-development-of-the-human-malarial-parasite-plasmodium-vivax
#10
Yongyut Pewkliang, Siriwan Rungin, Kaewta Lerdpanyangam, Apisak Duangmanee, Phongthon Kanjanasirirat, Phichaya Suthivanich, Khanit Sa-Ngiamsuntorn, Suparerk Borwornpinyo, Jetsumon Sattabongkot, Rapatbhorn Patrapuvich, Suradej Hongeng
BACKGROUND: Eradication of malaria is difficult because of the ability of hypnozoite, the dormant liver-stage form of Plasmodium vivax, to cause relapse in patients. Research efforts to better understand the biology of P. vivax hypnozoite and design relapse prevention strategies have been hampered by the lack of a robust and reliable model for in vitro culture of liver-stage parasites. Although the HC-04 hepatoma cell line is used for culturing liver-stage forms of Plasmodium, these cells proliferate unrestrictedly and detach from the culture dish after several days, which limits their usefulness in a long-term hypnozoite assay...
January 25, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29363364/insights-into-biological-activity-of-ureidoamides-with-primaquine-and-amino-acid-moieties
#11
Josipa Vlainić, Ivan Kosalec, Kristina Pavić, Dimitra Hadjipavlou-Litina, Eleni Pontiki, Branka Zorc
Primaquine (PQ) ureidoamides 5a-f were screened for antimicrobial, biofilm eradication and antioxidative activities. Susceptibility of the tested microbial species towards tested compounds showed species- and compound-dependent activity. N-(diphenylmethyl)-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]-4-methylpentanamide (5a) and 2-(4-chlorophenyl)-N-(diphenylmethyl)-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]acetamide (5d) showed antibacterial activity against S. aureus strains (MIC = 6...
December 2018: Journal of Enzyme Inhibition and Medicinal Chemistry
https://www.readbyqxmd.com/read/29361939/efficacy-and-safety-of-artemisinin-based-combination-therapy-and-chloroquine-with-concomitant-primaquine-to-treat-plasmodium-vivax-malaria-in-brazil-an-open-label-randomized-clinical-trial
#12
André Daher, Dhelio Pereira, Marcus V G Lacerda, Márcia A A Alexandre, Cristiana T Nascimento, Júlio Castro Alves de Lima E Silva, Mauro Tada, Rosilene Ruffato, Ivan Maia, Tereza Cristina Dos Santos, Paola Marchesini, Ana Carolina Santelli, David G Lalloo
BACKGROUND: There is general international agreement that the importance of vivax malaria has been neglected, and there is a need for new treatment approaches in an effort to progress towards control and elimination in Latin America. This open label randomized clinical trial evaluated the efficacy and safety of three treatment regimens using either one of two fixed dose artemisinin-based combinations or chloroquine in combination with a short course of primaquine (7-9 days: total dose 3-4...
January 24, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29357870/primaquine-ineligibility-in-anti-relapse-therapy-of-plasmodium-vivax-malaria-the-problem-of-g6pd-deficiency-and-cytochrome-p-450-2d6-polymorphisms
#13
EDITORIAL
J Kevin Baird, Katherine E Battle, Rosalind E Howes
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it awakens and provokes a clinical attack with attendant morbidity, risk of mortality, and opportunities for onward transmission. The only licensed drug that kills hypnozoites is primaquine, which attacks the hypnozoite reservoir but imposes serious obstacles in doing so-at hypnozoitocidal doses, it invariably causes a threatening acute haemolytic anaemia in patients having an inborn deficiency in glucose-6-phosphate dehydrogenase (G6PD), affecting about 8% of people living in malaria endemic nations...
January 22, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29347975/single-low-dose-primaquine-for-blocking-transmission-of-plasmodium-falciparum-malaria-a-proposed-model-derived-age-based-regimen-for-sub-saharan-africa
#14
W Robert Taylor, Htee Khu Naw, Kathryn Maitland, Thomas N Williams, Melissa Kapulu, Umberto D'Alessandro, James A Berkley, Philip Bejon, Joseph Okebe, Jane Achan, Alfred Ngwa Amambua, Muna Affara, Davis Nwakanma, Jean-Pierre van Geertruyden, Muhindo Mavoko, Pascal Lutumba, Junior Matangila, Philipe Brasseur, Patrice Piola, Rindra Randremanana, Estrella Lasry, Caterina Fanello, Marie Onyamboko, Birgit Schramm, Zolia Yah, Joel Jones, Rick M Fairhurst, Mahamadou Diakite, Grace Malenga, Malcolm Molyneux, Claude Rwagacondo, Charles Obonyo, Endalamaw Gadisa, Abraham Aseffa, Mores Loolpapit, Marie-Claire Henry, Grant Dorsey, Chandy John, Sodiomon B Sirima, Karen I Barnes, Peter Kremsner, Nicholas P Day, Nicholas J White, Mavuto Mukaka
BACKGROUND: In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), without testing for glucose-6-phosphate dehydrogenase deficiency (G6PDd), when treating patients with uncomplicated falciparum malaria. We sought to develop an age-based SLDPQ regimen that would be suitable for sub-Saharan Africa. METHODS: Using data on the anti-infectivity efficacy and tolerability of primaquine (PQ), the epidemiology of anaemia, and the risks of PQ-induced acute haemolytic anaemia (AHA) and clinically significant anaemia (CSA), we prospectively defined therapeutic-dose ranges of 0...
January 18, 2018: BMC Medicine
https://www.readbyqxmd.com/read/29342267/safety-of-single-dose-primaquine-in-g6pd-deficient-and-g6pd-normal-males-in-mali-without-malaria-an-open-label-phase-1-dose-adjustment-trial
#15
Ingrid Chen, Halimatou Diawara, Almahamoudou Mahamar, Koualy Sanogo, Sekouba Keita, Daouda Kone, Kalifa Diarra, Moussa Djimde, Mohamed Keita, Joelle Brown, Michelle E Roh, Jimee Hwang, Helmi Pett, Maxwell Murphy, Mikko Niemi, Bryan Greenhouse, Teun Bousema, Roly Gosling, Alassane Dicko
Background: The World Health Organization recommendation on the use of single low-dose primaquine (SLD-PQ) to reduce Plasmodium falciparum malaria transmission requires more safety data. Methods: We conducted an open-label, non-randomized, dose-adjustment trial of the safety of three single doses of primaquine in glucose-6-phosphate dehydrogenase (G6PD)-deficient adult males in Mali, followed by an assessment of safety in G6PD-deficient boys ages 11-17 years, and 5-10 years, including G6PD-normal control groups...
January 12, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29324864/safety-of-single-low-dose-primaquine-in-glucose-6-phosphate-dehydrogenase-deficient-falciparum-infected-african-males-two-open-label-randomized-safety-trials
#16
Guido J H Bastiaens, Alfred B Tiono, Joseph Okebe, Helmi E Pett, Sam A Coulibaly, Bronner P Gonçalves, Muna Affara, Alphonse Ouédraogo, Edith C Bougouma, Guillaume S Sanou, Issa Nébié, John Bradley, Kjerstin H W Lanke, Mikko Niemi, Sodiomon B Sirima, Umberto d'Alessandro, Teun Bousema, Chris Drakeley
BACKGROUND: Primaquine (PQ) actively clears mature Plasmodium falciparum gametocytes but in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals can cause hemolysis. We assessed the safety of low-dose PQ in combination with artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) in G6PDd African males with asymptomatic P. falciparum malaria. METHODS AND FINDINGS: In Burkina Faso, G6PDd adult males were randomized to treatment with AL alone (n = 10) or with PQ at 0...
2018: PloS One
https://www.readbyqxmd.com/read/29321371/assessing-drug-efficacy-against-plasmodium-falciparum-liver-stages-in-vivo
#17
Erika L Flannery, Lander Foquet, Vorada Chuenchob, Matthew Fishbaugher, Zachary Billman, Mary Jane Navarro, William Betz, Tayla M Olsen, Joshua Lee, Nelly Camargo, Thao Nguyen, Carola Schafer, Brandon K Sack, Elizabeth M Wilson, Jessica Saunders, John Bial, Brice Campo, Susan A Charman, Sean C Murphy, Margaret A Phillips, Stefan Hi Kappe, Sebastian A Mikolajczak
Malaria eradication necessitates new tools to fight the evolving and complex Plasmodium pathogens. These tools include prophylactic drugs that eliminate Plasmodium liver stages and consequently prevent clinical disease, decrease transmission, and reduce the propensity for resistance development. Currently, the identification of these drugs relies on in vitro P. falciparum liver stage assays or in vivo causal prophylaxis assays using rodent malaria parasites; there is no method to directly test in vivo liver stage activity of candidate antimalarials against the human malaria-causing parasite P...
January 11, 2018: JCI Insight
https://www.readbyqxmd.com/read/29317838/primaquine-double-dose-for-7-days-is-inferior-to-single-dose-treatment-for-14-days-in-preventing-plasmodium-vivax-recurrent-episodes-in-suriname
#18
M Sigrid Mac Donald-Ottevanger, Malti R Adhin, Jeetendra Kumar Jitan, Gustavo Bretas, Stephen Gs Vreden
Background: Recurrent episodes of Plasmodium vivax are caused by dormant liver stages of the parasite, which are not eradicated by choloroquine. Therefore, effective treatment also includes the use of primaquine (PQ). However, this secondary preventive therapy is often not effective, mostly due to poor adherence to the relatively long treatment course, justifying a comparative study of the efficacy of different durations of PQ treatment. Materials and methods: We included patients presenting with an acute and documented P...
2018: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29310655/methylene-blue-induced-morphological-deformations-in-plasmodium-falciparum-gametocytes-implications-for-transmission-blocking
#19
Ishan Wadi, C Radhakrishna Pillai, Anupkumar R Anvikar, Abhinav Sinha, Mahendra Nath, Neena Valecha
BACKGROUND: Malaria remains a global health problem despite availability of effective tools. For malaria elimination, drugs targeting sexual stages of Plasmodium falciparum need to be incorporated in treatment regimen along with schizonticidal drugs to interrupt transmission. Primaquine is recommended as a transmission blocking drug for its effect on mature gametocytes but is not extensively utilized because of associated safety concerns among glucose-6-phosphate dehydrogenase (G6PD) deficient patients...
January 8, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29305344/review-and-drug-therapy-implications-of-glucose-6-phosphate-dehydrogenase-deficiency
#20
REVIEW
Kristen D Belfield, Eric M Tichy
PURPOSE: The pathophysiology, diagnosis, and medication-use implications of glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common enzyme deficiency in humans, are reviewed. SUMMARY: Originally identified as favism in patients who experienced hemolysis after ingestion of fava beans, G6PD deficiency results from an X-linked chromosomal mutation that leads to reduced activity of the enzyme responsible for the final step of the pentose phosphate pathway, through which reduced nicotinamide adenine dinucleotide phosphate required for protection of cells from oxidative stress is produced...
February 1, 2018: American Journal of Health-system Pharmacy: AJHP
keyword
keyword
107853
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"